1. Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment.
- Author
-
Marchesoni D, Driul L, Mozzanega B, Nardelli GB, and Parenti A
- Subjects
- Breast Neoplasms drug therapy, Breast Neoplasms surgery, Carcinoma, Ductal drug therapy, Carcinoma, Ductal surgery, Chemotherapy, Adjuvant, Dilatation and Curettage, Endometrium drug effects, Endometrium pathology, Female, Humans, Hysteroscopy, Mastectomy, Radical, Middle Aged, Adenocarcinoma chemically induced, Anticarcinogenic Agents adverse effects, Antineoplastic Agents, Hormonal adverse effects, Carcinoma in Situ chemically induced, Endometrial Neoplasms chemically induced, Tamoxifen adverse effects
- Abstract
Case Report: In this paper we describe a case of endometrial carcinoma observed in a post-menopausal patient who was treated with tamoxifen for 5 years after a mastectomy for cancer. She came to our department because of vaginal bleeding 2 years after the end of tamoxifen treatment., Treatment: She underwent hysteroscopy and a D and C. A polypoid endometrium completely filled the uterine cavity and was carefully removed by curettage; histology showed a highly undifferentiated neoplasia with a component of serous adenocarcinoma, which was likely to originate from endometrial polyps., Outcome: The patient underwent radical hysterectomy, but no residual tumor was found in the uterus or in the tubes, ovary, or pelvic nodes, in spite of its low differentiation grade and high potential aggressiveness, and even though the patient was already symptomatic. Two years after surgery the patient is disease free, which is consistent with the evaluation of the surgical specimen, but unusual in poorly differentiated neoplasms.
- Published
- 2005
- Full Text
- View/download PDF